Dear Mr. Litle:

Please refer to your supplemental new drug application dated April 11, 2008, received April 14, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Children’s Zyrtec Allergy (cetirizine 5 mg/5 mL) syrup and Children’s Zyrtec Hives Relief (cetirizine 5 mg/5 mL) syrup.

This supplemental new drug application provides for a new bubblegum flavored, sugar-free formulation of Children’s Zyrtec Allergy syrup.

We have completed our review of this supplemental new drug application. This supplement is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the draft labeling (15 mL, 2 fl. oz. and 4 fl. oz. carton and container labels for Children’s Zyrtec Allergy syrup submitted April 11, 2008), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplement NDA 22-155/S-003.” Approval of this submission by FDA is not required before the labeling is used.

We remind you to remove the phrase “New Flavor!” from the principal display panel (PDP) after 180 days of marketing.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:
We remind you that you must comply with the requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Elaine Abraham, Regulatory Project Manager, at (301) 796-0843.

Sincerely,

{See appended electronic signature page}

Joel Schiffenbauer, M.D.
Deputy Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Joel Schiffenbauer
8/14/2008 06:58:09 AM